NCT04739345View on ClinicalTrials.gov

Effect of Pentoxifylline on Prognosis of Coronavirus Disease 2019 (COVID- 19) Infection

NACompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

June 1, 2021

Study Completion Date

October 1, 2022

Conditions
Covid19Corona Virus InfectionCytokine Storm
Interventions
DRUG

Pentoxifylline

400 mg of pentoxifylline orally TID with the standard COVID-19 protocol of the Egyptian Ministry of Health

Trial Locations (1)

11314

Teachers Hospital, Cairo

All Listed Sponsors
collaborator

Misr International University

OTHER

lead

Ain Shams University

OTHER

NCT04739345 - Effect of Pentoxifylline on Prognosis of Coronavirus Disease 2019 (COVID- 19) Infection | Biotech Hunter | Biotech Hunter